XBiotech Announces Oral Presentation of Atopic Dermatitis Results for Bermekimab at 2019 EADV Congress in Madrid, Spain

September 27, 2019

Results of the Company's Phase 2 Trial to be Presented by Dr. Alice Gottlieb on Saturday, October 12, 2019

AUSTIN, Texas, Sept. 27, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today that Dr. Alice Gottlieb will be presenting clinical findings for bermekimab in the treatment of atopic dermatitis (AD) at the European Academy of Dermatology and Venereology (EADV) Congress being held in Madrid Spain October 9-13th. Dr. Gottlieb will present data from a multicenter, phase 2 study in which bermekimab monotherapy showed rapid and dose dependent improvement in AD. The presentation will be given during the October 12th morning session for late breaking clinical data, Chaired by Professor Brigitte Dreno. A subset of these data were presented at the American Academy of Dermatology conference in Washington, D.C. in March of this year.

A highlight of the data to be reported is the observation that after only 8 weeks of bermekimab therapy, three-fourths of patients achieved 75% improvement in their Eczema Area and Severity Index (EASI 75) scores, a key measure of disease severity in AD. The current standard of care and the only approved biological therapy for AD involves a 16 week treatment regimen, which clinical trials have shown to result in 44-51% of patients achieving 75% improvement in EASI score. Another key finding to be reported in the bermekimab study was a dramatic reduction in itch, which can be debilitating in eczema patients. An overall reduction of ≥4 points based on the Numerical Rating Scale for itch is considered clinically significant. Seventy-five percent of patients achieved ≥4 point reduction in 8 weeks.

Atopic dermatitis, commonly referred to as eczema, is characterized by chronic inflammation of the skin, which results in a breakdown of the skin barrier and leads to dry, thickened, scaly skin, redness, and itching, the latter which can be debilitating and result in significant sleep disturbances and loss of quality of life. There's an estimated 18 million people with AD in the United States and the incidence is believed to be increasing in industrialized countries. Nearly 7 million persons in the U.S. are believed to have atopic dermatitis that is considered moderate to severe, which is the disease severity of subjects treated in the present study. The economic impact of AD is significant, with an estimate of nearly $40 billion in costs annually.

About True Human™ Therapeutic Antibodies
XBiotech's True Human™ antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ proprietary technologyXBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930

Source: XBiotech Inc.